Miao Hui, Wang Nuan, Shi Lin-Xin, Wang Zheng, Song Wen-Bo
1Department of Radiotherapy, Xuzhou Cancer Hospital, Xuzhou, 221000 People's Republic of China.
2Department of Neurology, Xuzhou No. 1 People's Hospital, Xuzhou, 221002 People's Republic of China.
Cancer Cell Int. 2019 May 23;19:147. doi: 10.1186/s12935-019-0852-8. eCollection 2019.
Accumulating evidence has highlighted the tumor suppressive roles of microRNA (miRNAs) in cervical cancer (CC). In the present study, we aim to delineate the functional relevance of microRNA-137 (miR-137) in influencing epithelial-mesenchymal transition (EMT), and other CC cell biological activities via the TGF-β/smad pathway by binding to GREM1.
Microarray analysis was initially adopted to predict the differentially expressed genes and the miRNAs related to CC, followed by the measurement of the expression patterns of GREM1, EMT-related factors in the CC tissues and the adjacent tissues. Dual luciferase reporter gene assay was conducted to determine the relationship between miR-137 and GREM1. Gain-of- and loss-of-function experiments were conducted to characterize the effects of miR-137 and GREM1 on the colony formation, proliferation, apoptosis, migration, and invasion of CC cells in vitro, and the tumorigenicity of the CC cells in nude mice. The TGF-β/smad pathway was subsequently blocked with si-TGF-β to investigate its involvement.
Reduced miR-137 expression and increased GREM1 expression were predicted in CC, which was subsequently observed in the CC tissues and cells. Notably, GREM1 was a target gene of miR-137. The overexpressed miR-137 was found to inhibit EMT, cell proliferation, colony formation, invasion, migration and tumorigenesis in nude mice. In addition, miR-137 was noted to inhibit the activation of the TGF-β/smad pathway by binding to GREM1. The silencing of TGF-β1 was shown to reverse the effects induced by downregulated expression of miR-137.
This study suggests that upregulated miR-137 suppresses the tumor progression in CC via blocking the TGF-β/smad pathway by binding to and negatively regulating GREM1.
越来越多的证据表明,微小RNA(miRNA)在宫颈癌(CC)中发挥肿瘤抑制作用。在本研究中,我们旨在通过与GREM1结合,阐明微小RNA-137(miR-137)通过TGF-β/ smad途径影响上皮-间质转化(EMT)及其他CC细胞生物学活性的功能相关性。
首先采用基因芯片分析预测与CC相关的差异表达基因和miRNA,随后检测CC组织和癌旁组织中GREM1、EMT相关因子的表达模式。采用双荧光素酶报告基因检测法确定miR-137与GREM1之间的关系。进行功能获得和功能缺失实验,以表征miR-137和GREM1对CC细胞体外集落形成、增殖、凋亡、迁移和侵袭以及CC细胞在裸鼠体内致瘤性的影响。随后用si-TGF-β阻断TGF-β/ smad途径,以研究其参与情况。
预测CC中miR-137表达降低,GREM1表达增加,随后在CC组织和细胞中观察到这一现象。值得注意的是,GREM1是miR-137的靶基因。发现过表达的miR-137可抑制EMT、细胞增殖、集落形成、侵袭、迁移以及裸鼠体内的肿瘤发生。此外,miR-137通过与GREM1结合抑制TGF-β/ smad途径的激活。TGF-β1沉默可逆转miR-137表达下调所诱导的效应。
本研究表明,上调的miR-137通过与GREM1结合并负向调节GREM1,阻断TGF-β/ smad途径,从而抑制CC的肿瘤进展。